Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanoparticle Technology To Treat Vascular Occlusions Using Much-Lower Drug Doses

This article was originally published in Start Up

Executive Summary

New research shows that aggregates of nanoparticles will target an occluded blood vessel, responding to the higher shear force present as blood flows through the blockage. When coated with the anti-clotting drug tPA, the nanoparticles dissolve clots at one-hundredth the therapeutic dose of tPA, suggesting a much broader potential clinical use for that drug. This proof of concept also suggests that the nanoparticle technology may be applied to target any disease characterized by vessel constriction, including stroke and heart attack.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092357

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel